Form 4: Vistagen Therapeutics Director Rotunno Receives Stock Options

Mary L. Rotunno, a director at Vistagen Therapeutics, was granted stock options to purchase 14,100 shares of common stock on September 6, 2024.

Summary

• Mary L. Rotunno, a director of Vistagen Therapeutics, Inc., received stock options on September 6, 2024.
• The options grant the right to buy 14,100 shares of Vistagen's common stock at an exercise price of $3.25 per share.
• 25% of the options vested immediately on the grant date, with the remaining options vesting in 12 equal monthly installments.
• The options will be fully vested one year from the grant date and expire on September 6, 2034.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to stock option grants, which is neither particularly positive nor negative.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes the director to remain with the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of 25% immediately and the remainder over 12 months is a fairly typical arrangement.
• Comparing the size of this grant to similar companies and director roles would require further analysis of Vistagen's compensation policies and industry benchmarks.

Stakeholder Impact

• The stock option grant could have a minor positive impact on shareholder sentiment as it aligns the director's interests with the company's performance.

Key Dates